Medindia LOGIN REGISTER
Medindia
Advertisement

LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies

Wednesday, September 19, 2007 General News
Advertisement
BOZEMAN, Mont., Sept. 18 LigoCyte Pharmaceuticals, Inc.,today announced a strategic partnership with Biogen Idec (Nasdaq: BIIB) todevelop therapies targeting CD103 for the treatment of chronic inflammatorydiseases including potential respiratory, gastrointestinal, and autoimmuneindications. CD103 is the unique alphaE-beta7 integrin that has beenimplicated in the activation, homing and retention of lymphocytes that mediateinflammatory diseases affecting mucosal regions of the intestine, skin, andlungs.
Advertisement

Under terms of the agreement, LigoCyte will receive milestone payments onthe successful development of drug candidates. The collaboration includes anopportunity for co-development, co-promotion, and sharing of profits resultingfrom commercialized products.
Advertisement

"We are very pleased to be entering into this collaboration with BiogenIdec for the development of our lead anti-inflammatory therapy," said DonaldP. Beeman, CEO and chairman of the board for LigoCyte. "This strategicalliance confirms the value of LigoCyte's immunology expertise."

About LigoCyte

LigoCyte Pharmaceuticals, Inc., is a privately held biopharmaceuticalcompany developing vaccines and therapeutic monoclonal antibodies focused onimportant respiratory and gastrointestinal markets. The company is currentlyinvestigating its norovirus vaccine in human clinical studies. For moreinformation on LigoCyte, please visit http://www.ligocyte.com.

SOURCE LigoCyte Pharmaceuticals, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close